Eric Christensen, MD
Otolaryngology · Kansas City, MONPI 1962478503
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 191 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 34 manufacturers, the largest accounting for just 13.0% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $1,041, 4.2 times the $249 reported in 2019.
Across 191 payments — averaging $20.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$503
- Johnson & Johnson$493
- Optinose US, Inc.$423
- GSK$381
- UCB, Inc.$298
- Sanofi$249
- plus $2K from 28 others
What the payments were for
- Food & beverage$3,877100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 30 | $503 |
| Johnson & Johnson(2 entities) | 22 | $493 |
| Optinose US, Inc. | 23 | $423 |
| GSK | 18 | $381 |
| UCB, Inc. | 13 | $298 |
| Sanofi | 13 | $249 |
| Regeneron Healthcare Solutions, Inc. | 7 | $181 |
| Amgen | 8 | $144 |
| Grifols USA, LLC | 4 | $105 |
| Acclarent, Inc | 4 | $104 |
| Organogenesis Inc. | 4 | $92 |
| Aerin Medical Inc. | 4 | $89 |
| AbbVie | 4 | $86 |
| Almirall LLC | 3 | $77 |
| Sun Pharmaceutical Industries Inc. | 4 | $75 |
| Stryker | 3 | $72 |
| Intersect ENT, Inc. | 2 | $71 |
| Biofrontera Inc. | 3 | $50 |
| Incyte Corporation | 2 | $46 |
| Jazz Pharmaceuticals Inc. | 2 | $43 |
| Hologic Sales And Service, LLC | 2 | $33 |
| Medtronic | 1 | $29 |
| E.r. Squibb & Sons, L.L.C. | 1 | $28 |
| AstraZeneca | 2 | $28 |
| LEO Pharma Inc. | 1 | $25 |
| Mallinckrodt Hospital Products Inc. | 1 | $24 |
| Kowa Pharmaceuticals America, Inc. | 2 | $23 |
| Merck | 1 | $19 |
| VYNE Pharmaceuticals Inc. | 1 | $18 |
| Kyowa Kirin, Inc. | 1 | $14 |
| Helsinn Therapeutics (U.S.), Inc. | 1 | $14 |
| Endogastric Solutions, Inc | 2 | $13 |
| Agiliti Surgical, Inc. | 1 | $13 |
| Hospira, Inc. | 1 | $12 |
How this compares
$3,877 in reported general payments places this provider in the 80th percentile of 210 otolaryngology providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dupixent SyringeDupilumab | 13 | $47,594 |
| Ipratropium Bromide | 365 | $15,946 |
| Famotidine | 640 | $11,030 |
| Azelastine Hcl | 241 | $8,378 |
| Fluticasone Propionate | 304 | $5,947 |
| Pantoprazole Sodium | 260 | $4,505 |
| Arnuity ElliptaFluticasone Furoate | 11 | $3,982 |
| Montelukast Sodium | 245 | $1,792 |
| Doxycycline Hyclate | 99 | $1,421 |
| Pilocarpine Hcl | 16 | $1,313 |
| Fluocinolone Acetonide Oil | 13 | $903 |
| Omeprazole | 84 | $775 |
| Triamterene-HydrochlorothiazidTriamterene/Hydrochlorothiazid | 96 | $702 |
| Mupirocin | 74 | $665 |
| Ofloxacin | 22 | $452 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKArnuity Ellipta | $381 | $3,98211 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 210 otolaryngology providers in Missouri.
Other otolaryngology in Kansas City
- Talon ManingasJoplin$314K
- Ryan JacksonSaint Louis$284K
- Ravindra UppaluriSaint Louis$168K
- James GouldFestus$143K
- John SchneiderSaint Louis$74K
- Amit WaliaSaint Louis$21K
- Bharat PanugantiSaint Louis$19K
- Jeffrey SharonSt. Louis$18K
- Kelvin WallsLees Summit$14K
- Cristine Klatt-CromwellSaint Louis$13K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.